Cancer News and Research

Latest Cancer News and Research

PCI-32765 produces durable remissions in Phase I/II CLL clinical trial

A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

New data from TetraLogic's TL32711 study on AML presented at 53rd ASH meeting

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the oral presentation of new data on its Smac mimetic drug candidate TL32711 at the 53rd ASH Annual Meeting and Exposition in San Diego.

12 Dec 2011

HER2 proteins do not predict breast cancer patient's outcome after Herceptin treatment

Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers.

12 Dec 2011

Gene therapy can reduce painful bleeding episodes in patients with hemophilia B

Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children's Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.

12 Dec 2011

Many postmenopausal women quit breast cancer drugs early because of side effects

Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves -- as well as the largest, most scientifically rigorous study to examine the question -- reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.

12 Dec 2011

People in Northern Ireland less likely to develop cancers

People in Northern Ireland have a lower risk of developing some cancers than those living in the Republic of Ireland, according to the All-Ireland Cancer Atlas - a collaborative publication by the Northern Ireland Cancer Registry at Queen's University Belfast and the National Cancer Registry in Cork.

12 Dec 2011

Study describes miR-124 can prevent and treat liver cancer

Cancer of the liver - rare in the United States but the third-leading cause of cancer death worldwide - can result from environmental exposures or infections like chronic hepatitis, but the link is poorly understood.

12 Dec 2011

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced the initiation of two clinical studies for the nucleotide analogues ALS-2200 and ALS-2158, which are inhibitors of the hepatitis C NS5B polymerase.

12 Dec 2011

PSA testing that combines blood test with other factors can help men avoid prostate biopsies

Prostate cancer screening that combines an adjusted blood test with other factors including the size of the gland, the patient's overall weight and family history, can help up to one-quarter of men avoid biopsies and the risks associated with them, a Beth Israel Deaconess Medical Center-led research team says.

12 Dec 2011

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Memgen, LLC announces the following abstract on ISF35, the Company's lead product, will be presented during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA.

12 Dec 2011

Exact Sciences completes underwritten public offering of common stock

Exact Sciences Corp. today announced that it has completed its previously announced underwritten public offering of its common stock at a price of $8.00 per share to the public.

12 Dec 2011

Positive data from Aeterna Zentaris AEZS-131 preclinical study on TNBC

Aeterna Zentaris Inc. today announced positive preclinical data in triple-negative breast cancer (TNBC) for its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131.

11 Dec 2011

Breast cancer hope with new drug and new combination regimens

last week at the San Antonio Breast Cancer Symposium, researchers announced encouraging results from studies of two cancer medications that appeared to keep breast cancer from advancing.

11 Dec 2011

Researchers discover molecular marker for immediate precursors of blood stem cells

A research team led by Nancy Speck, PhD, professor of Cell and Developmental Biology at the Perelman School of Medicine at the University of Pennsylvania, has discovered a molecular marker for the immediate precursors of hematopoietic (blood) stem cells (HSCs) in the developing embryo, which provides much-needed insights for making these cells from engineered precursors.

9 Dec 2011

Signal Genetics to launch second generation Myeloma product, MyPRS Plus

Signal Genetics announced today, at the American Society of Hematology Annual Meeting, that the Company is launching its next generation Multiple Myeloma product, MyPRS Plus, effective January 1, 2012.

9 Dec 2011

Panel recommends close monitoring and delay of treatment for localized, low-risk prostate cancer

An independent panel convened this week by the National Institutes of Health has concluded that many men with localized, low-risk prostate cancer should be closely monitored, permitting treatment to be delayed until warranted by disease progression.

9 Dec 2011

Study explains molecular basis for cherubism disease

The Samuel Lunenfeld Research Institute's Drs. Frank Sicheri, Tony Pawson and Sebastian Guettler, in collaboration with Dr. Robert Rottapel at the Ontario Cancer Institute, have uncovered the detailed architecture of a crucial component of Tankyrase, a protein linked to the bone development disorder cherubism and involved in a myriad of cellular processes.

9 Dec 2011

Researchers reveal contribution of telomerase in controlling genetic code integrity

Researchers have revealed how a molecule called telomerase contributes to the control of the integrity of our genetic code, and when it is involved in the deregulation of the code, its important role in the development of cancer.

9 Dec 2011

The contraceptive pill could reduce risk of ovarian and uterine cancer in nuns

Professor Roger Short, from the University of Melbourne, and Dr Kara Britt, from Monash University, argue in a comment piece in The Lancet, that since the contraceptive pill reduces overall mortality and mortality specifically linked to ovarian and uterine cancer, nuns should be given the pill for health, rather than contraceptive, reasons.

9 Dec 2011

Trastuzumab improves long-term outcomes in obese patients with HER2-positive breast cancer

A large, multicenter, randomized study has shown that obese patients with HER2-positive breast cancer have larger tumors, increased lymph node involvement and, when not treated with trastuzumab, poorer long-term outcomes than normal-weight patients.

9 Dec 2011